文献速递免疫规划

日本腮腺炎疫苗接种后不良事件的年度趋势:一项回顾性研究

Annual trends in adverse events following mumps vaccination in Japan: A retrospective study.
PubMed 文献 · Vaccine · 2022-01-17

该研究利用疫苗制造商1992至2018年收集的医疗机构腮腺炎疫苗接种后不良事件数据及Torii株腮腺炎疫苗年度发货量,计算每10万剂次不良事件发生率及95%CI。结果显示无菌性脑膜炎发生率自2001年起显著下降,2010年后稳定在每10万剂次3例以下。

要点

  • 1992至2018年共发货8,262,121剂腮腺炎疫苗,688名受试者报告不良事件。
  • 全部不良事件发生率为8.33/10万剂,无菌性脑膜炎为4.19/10万剂。
  • 无菌性脑膜炎发生率从1998至2000年的7.90/10万剂降至2016至2018年的2.78/10万剂。

核心结论

  • 疫苗接种后无菌性脑膜炎发生率自2001年以来显著下降,自2010年以来一直稳定在每10万剂次3例以下。

研究设计与样本

  • 回顾性观察性研究,使用疫苗制造商收集的1992年至2018年医疗机构腮腺炎疫苗接种后不良事件数据,并获取Torii株腮腺炎疫苗年度发货量。

主要发现

  • 研究期间共发货8,262,121剂腮腺炎疫苗,688名受试者报告不良事件。
  • 全部不良事件发生率为8.33/10万剂,无菌性脑膜炎为4.19/10万剂,脑炎为0.33/10万剂,腮腺炎为0.80/10万剂,腮腺炎并发症为0.25/10万剂,其他为3.78/10万剂。
  • 无菌性脑膜炎发生率在1998至2000年间为7.90/10万剂(95%CI:5.61-10.18),在2001至2003年间下降一半至3.91/10万剂(95%CI:2.46-5.36)。
  • 2016至2018年间无菌性脑膜炎最新发生率为2.78/10万剂(95%CI:1.94-3.62)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Japan, a monovalent mumps vaccine is provided on a voluntary basis. Due to public concerns over post-vaccination aseptic meningitis, the vaccination coverage is not high enough. The present study investigated the incidence of adverse events, including aseptic meningitis, after Torii strain-derived mumps vaccination. METHODS: This retrospective, observational study used data collected by a vaccine manufacturer regarding adverse events following mumps vaccinations at medical institutions between 1992 and 2018. In addition, the number of Torii strain-derived mumps vaccines shipped each year was obtained. The incidence (per 100,000 doses) and 95% confidence intervals (CIs) were calculated for all adverse events and each adverse event, categorized as aseptic meningitis, encephalitis, mumps, mumps complications, and others. RESULTS: During the study period, 8,262,121 mumps vaccine doses were shipped, and 688 subjects reported adverse events. The incidence for all adverse events (per 100,000 doses) was 8.33, and the incidence was 4.19 for aseptic meningitis, 0.33 for encephalitis, 0.80 for mumps, 0.25 for mumps complications, and 3.78 for others. The incidence of aseptic meningitis (per 100,000 doses) was 7.90 (95% CI: 5.61-10.18) between 1998 and 2000 but declined by half, to 3.91 (2.46-5.36), between 2001 and 2003. The most recent incidence (per 100,000 doses) of aseptic meningitis, for the period 2016 to 2018, was 2.78 (1.94-3.62). CONCLUSION: The incidence of post-vaccination aseptic meningitis has declined significantly since 2001, and the incidence has remained stable at fewer than 3 cases per 100,000 doses since 2010. Multiple factors might have contributed to the decline in aseptic meningitis incidence, including (i) lowered misclassification of aseptic meningitis resulting from echovirus infection; (ii) changes in the vaccine manufacturing process in 2000; and (iii) publication in 2008 of the recommendation for vaccination of children at 1 year of age.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ohfuji S, Tanaka T, Nakano T, et al. Annual trends in adverse events following mumps vaccination in Japan: A retrospective study. Vaccine. 2022. PMID: 35058077. doi:10.1016/j.vaccine.2022.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。